Skip to main content

Vanderbilt Vaccine Research Program Archives

VUMC-led study finds Moderna COVID vaccine safe and effective for children

May. 12, 2022—  by Bill Snyder Moderna’s COVID-19 vaccine is safe and generates robust immune responses in children ages 6 to 11 years, a national clinical trial co-led by Vanderbilt University Medical Center vaccine expert C. Buddy Creech, MD, MPH, has found. The two-dose vaccine (given approximately one month apart) led to antibody responses in more than...

Read more


MIS-C diagnosis rare in vaccinated children with no previous COVID-19 diagnosis

Feb. 24, 2022—A Vanderbiltl study found that children who received the COVID-19 vaccine who had not previously been diagnosed with COVID infection are unlikely to be diagnosed with multisystem inflammatory syndrome in children (MIS-C).

Read more


Study finds shorter treatment better for young children with outpatient pneumonia

Feb. 3, 2022—A Vanderbilt study found that five days of antibiotics is superior to 10 days for children with community-acquired pneumonia who are not hospitalized.

Read more


Weigh risks, plan ahead prior to gathering for the holidays

Dec. 8, 2021—Vanderbilt University Medical Center infectious disease experts advise this is the season to think very wisely about planned get-togethers.

Read more


Heparin, platelets discouraged as treatment for blood clots after COVID vaccine

May. 12, 2021—Heparin and platelets are discouraged as treatment for patients who develop blood clots in the brain and low platelet counts 6-15 days after receiving Johnson & Johnson’s Janssen COVID-19 vaccine, following a clinical investigation review of 12 U.S. cases conducted by the CDC and institutions including Vanderbilt University Medical Center.

Read more


Investigational vaccine to be tested against COVID-19 variant

Apr. 2, 2021—Vanderbilt University Medical Center is participating in a national phase 1 clinical trial in healthy adults of an investigational vaccine against the B.1.351 variant of the COVID-19 virus that was first identified in South Africa.

Read more


Coronavirus ‘crusaders’ spur VUMC research achievements

Dec. 16, 2020—The development of the vaccines, monoclonal antibodies and antiviral drugs that ultimately will defeat COVID-19 wouldn’t have been possible had it not been for the unflagging and selfless efforts of a global army of research nurses, laboratory personnel, recruiters and other staff.

Read more


VUMC begins study of second COVID-19 vaccine

Nov. 2, 2020—Vanderbilt University Medical Center has begun recruiting up to 250 participants for a Phase 3 clinical trial testing an investigational COVID-19 vaccine candidate developed by the Janssen Pharmaceutical Companies of Johnson & Johnson.

Read more


Remdesivir helps reduce COVID-19 recovery time: study

Jun. 4, 2020—The investigational antiviral drug remdesivir can shorten the time to recovery in adults hospitalized with COVID-19, according to preliminary results of a clinical trial published last month in The New England Journal of Medicine.

Read more


Vanderbilt investigators encouraged by early results of placebo-controlled remdesivir trial

Apr. 29, 2020—A preliminary look at data from hospitalized adults diagnosed with coronavirus disease 2019 (COVID-19) in a randomized, controlled clinical trial to evaluate the safety and efficacy of the investigational antiviral remdesivir is showing promising results.

Read more


Vaccine Program receives NIH renewal of VTEU

Feb. 5, 2020—The Vanderbilt Vaccine Research Program has received a grant from the NIH to continue its work as one of the nation’s nine Vaccine and Treatment Evaluation Units.

Read more


Vaccine Program receives NIH renewal of VTEU

Jan. 23, 2020—The Vanderbilt Vaccine Research Program (VVRP) has received a grant from the National Institutes of Health (NIH) to continue its work as one of the nation’s nine Vaccine and Treatment Evaluation Units (VTEUs).

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more